Apple | Mobile |
---|---|
Business Dev & Design Entertainment | Social Media Tech Web Video |
Apple | Mobile |
---|---|
Business Dev & Design Entertainment | Social Media Tech Web Video |
Develops vaccines to protect against emerging infectious diseases.
Year Established: | |
Funding: | 15 |
Address: | Fort Collins, CO 80525 |
Telephone: | 2147483647 |
Mobile: | |
Fax: | 970.372.0693 |
Mail: | info@inviragen.com |
Company URL: | http://www.inviragen.com |
Careers
Career opportunities
Inviragen is seeking talented, motivated professionals who will thrive in our highly productive, results-oriented, and collaborative culture. Inviragen is an Equal Opportunity Employer with competitive compensation and benefits.
Please submit one resume for all positions for which you are applying. It is not necessary to send additional copies of your resume, unless critical information (i.e., name or address) has changed.
Bio*One Capital,Charter Life Sciences,Phillip Private Equity Pte, Ltd. (FKA: ECICS Mgt. Pte, Ltd.),Venture Investors LLC
Dr. Dan Stinchcomb Co-founder and CEO
Dr. Stinchcomb has over 19 years of biotechnology experience including research, product development, approval, and commercialization of vaccines, therapeutics, and diagnostics. His background includes positions as Executive Vice President of Research and Development at Heska Corporation, Director of Biology at Ribozyme Pharmaceuticals (now Sirna acquired by Merck), and Senior Scientist at Synergen (acquired by Amgen).
Prior to his career in biotechnology, Dr. Stinchcomb was Assistant and Associate Professor at Harvard University. He obtained his Ph.D. at Stanford University and his B.A. at Harvard University. Currently, he serves as an Adjunct Professor of Biochemistry and Molecular Biology at Colorado State University.
Dr. Jorge Osorio Co-founder and CSO
Dr. Osorio has over 18 years of vaccine research and development experience in academia and industry. Dr. Osorio co-founded Inviragen with Dr. Stinchcomb in 2003 and currently serves as Assistant Professor in the Department of Pathobiological Sciences at the University of Wisconsin. At the University, Dr. Osorio's research centers on molecular vaccines for tropical diseases such as dengue and yellow fever as well as biodefense for plague and poxviruses.
Prior to founding Inviragen and joining the University of Wisconsin, Dr. Osorio held senior scientific and global project leadership positions at Chiron Vaccines, Powderject, Merial, and Heska Corporation. Dr. Osorio has created and demonstrated proof-of-principal for innovative vaccines to protect against influenza, hepatitis B, viral encephalitis, rabies, and plague. Dr. Osorio received his PhD from the University of Wisconsin and DVM from Universidad de Antioquia, Colombia.
Mr. Paul Hudnut Director, Chairman
Mr. Hudnut teaches entrepreneurship at the College of Business at Colorado State University and is co-director of CSU's Global Innovation Center for Energy, Health and the Environment. He is also the founder and director of EnviroFit International, Ltd. Mr. Hudnut's experience includes positions as Vice President of Business Development for PR Pharmaceuticals, Executive Vice President for Business Development at Heska Corporation, and management positions at US WEST.